Review

antibodies against fabp5 (Proteintech)

Name: antibodies against fabp5
Brand: Proteintech
Rating: 86 (1 reviews)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech antibodies against fabp5
Antibodies Against Fabp5, supplied by Proteintech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against fabp5/product/Proteintech
Average 86 stars, based on 1 article reviews

antibodies against fabp5 - by Bioz Stars, 2025-02

86/100 stars

Images

Image Search Results

FABP5 is upregulated in HCC and associated with a poor prognosis. ( A ) FABP5 protein levels for ten cancers in the CPATC database. ( B ) Protein expression of FABP5 in HCC in CPATC database. ( C ) The expression of FABP5 in the TCGA database is related to the stage of LIHC. ( D ) The TCGA database showed that FABP5 expression was negatively correlated with the overall survival time of HCC patients.

Journal: Biology

Article Title: LncRNA495810 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells by Interacting with FABP5

doi: 10.3390/biology13080644

Figure Lengend Snippet: FABP5 is upregulated in HCC and associated with a poor prognosis. ( A ) FABP5 protein levels for ten cancers in the CPATC database. ( B ) Protein expression of FABP5 in HCC in CPATC database. ( C ) The expression of FABP5 in the TCGA database is related to the stage of LIHC. ( D ) The TCGA database showed that FABP5 expression was negatively correlated with the overall survival time of HCC patients.

Article Snippet: Cells were collected from a 100 mm culture dish and lysed on ice using Western/IP cell lysis solutions (Beyotime, Shanghai, China) for 1 h. After centrifuging, a small portion of the cell lysis supernatant was obtained for Western blot analysis, while the other portion was mixed with antibodies against FABP5 or IgG overnight.

Techniques: Expressing

LncRNA495810 binds to FABP5 and promotes its expression. ( A and B ) RNA pull-down assay ( A ) and RIP assay ( B ) were conducted to determine the interaction between lncRNA495810 and FABP5. ( C ) RT-qPCR was performed to detect the effect of lncRNA495810 overexpression (495810) on the mRNA level of FABP5. ( D ) RT-qPCR was performed to detect the effect of lncRNA495810 knockdown (sh7, sh2660) on the mRNA level of FABP5. ( E ) Western blot was conducted to detect the effect of lncRNA495810 overexpression (495810) on FABP5 protein level. ( F ) Western blot was conducted to detect the effect of lncRNA495810 knockdown (sh7, sh2660) on FABP5 protein level. * p < 0.05, ** p < 0.01, *** p < 0.001.

Journal: Biology

Article Title: LncRNA495810 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells by Interacting with FABP5

doi: 10.3390/biology13080644

Figure Lengend Snippet: LncRNA495810 binds to FABP5 and promotes its expression. ( A and B ) RNA pull-down assay ( A ) and RIP assay ( B ) were conducted to determine the interaction between lncRNA495810 and FABP5. ( C ) RT-qPCR was performed to detect the effect of lncRNA495810 overexpression (495810) on the mRNA level of FABP5. ( D ) RT-qPCR was performed to detect the effect of lncRNA495810 knockdown (sh7, sh2660) on the mRNA level of FABP5. ( E ) Western blot was conducted to detect the effect of lncRNA495810 overexpression (495810) on FABP5 protein level. ( F ) Western blot was conducted to detect the effect of lncRNA495810 knockdown (sh7, sh2660) on FABP5 protein level. * p < 0.05, ** p < 0.01, *** p < 0.001.

Techniques: Expressing, Pull Down Assay, Quantitative RT-PCR, Over Expression, Knockdown, Western Blot

FABP5 mediates the promoting effect of lncRNA495810 in HCC cells. ( A ) The cell proliferation was analyzed by Edu assay after HepG2 cells were cotransfected with empty plasmid (pCDH + siNC) or lncRNA495810 overexpression plasmid (495810 + siNC) and FABP5 siRNA (siFABP5). The proliferation capacity of HepG2 cells was determined by Edu assay (×200). ( B , C ) The effect of cell migration was analyzed by wound healing assay ( B ) and Transwell assay ( C ) after HepG2 cells were cotransfected with empty plasmid (pCDH + siNC) or lncRNA495810 overexpression plasmid (495810 + siNC) and FABP5 siRNA (siFABP5). The migration ability of HepG2 cells was determined by migration assay (×200). ( D ) The expression of EMT-related proteins was detected using Western blot assay after HepG2 cells were cotransfected with empty plasmid (pCDH + siNC) or lncRNA495810 overexpression plasmid (495810 + siNC) and FABP5 siRNA (siFABP5). * p < 0.05.

Journal: Biology

Article Title: LncRNA495810 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells by Interacting with FABP5

doi: 10.3390/biology13080644

Figure Lengend Snippet: FABP5 mediates the promoting effect of lncRNA495810 in HCC cells. ( A ) The cell proliferation was analyzed by Edu assay after HepG2 cells were cotransfected with empty plasmid (pCDH + siNC) or lncRNA495810 overexpression plasmid (495810 + siNC) and FABP5 siRNA (siFABP5). The proliferation capacity of HepG2 cells was determined by Edu assay (×200). ( B , C ) The effect of cell migration was analyzed by wound healing assay ( B ) and Transwell assay ( C ) after HepG2 cells were cotransfected with empty plasmid (pCDH + siNC) or lncRNA495810 overexpression plasmid (495810 + siNC) and FABP5 siRNA (siFABP5). The migration ability of HepG2 cells was determined by migration assay (×200). ( D ) The expression of EMT-related proteins was detected using Western blot assay after HepG2 cells were cotransfected with empty plasmid (pCDH + siNC) or lncRNA495810 overexpression plasmid (495810 + siNC) and FABP5 siRNA (siFABP5). * p < 0.05.

Techniques: EdU Assay, Plasmid Preparation, Over Expression, Migration, Wound Healing Assay, Transwell Assay, Expressing, Western Blot

Genetic alternation of FABP family members in various cancer types. A-B: Genetic alternation of each FABP family member ( FABP1 , FABP2 , FABP3 , FABP4 , FABP5 , FABP6 , FABP7 , PMP2 , FABP9 and FABP12 ) in pan-cancer types (70655 samples from 217 non-redundant studies) (A) and in various liver cancer subtypes (1829 samples from eleven studies) (B) using The Cancer Genome Atlas datasets. The mutation frequency for each FABP gene was shown next to the gene name; C: Co-occurrence of genetic alternation of the gene loci of FABP family members in liver cancer.

Journal: World Journal of Clinical Oncology

Article Title: Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma

doi: 10.5306/wjco.v15.i1.130

Figure Lengend Snippet: Genetic alternation of FABP family members in various cancer types. A-B: Genetic alternation of each FABP family member ( FABP1 , FABP2 , FABP3 , FABP4 , FABP5 , FABP6 , FABP7 , PMP2 , FABP9 and FABP12 ) in pan-cancer types (70655 samples from 217 non-redundant studies) (A) and in various liver cancer subtypes (1829 samples from eleven studies) (B) using The Cancer Genome Atlas datasets. The mutation frequency for each FABP gene was shown next to the gene name; C: Co-occurrence of genetic alternation of the gene loci of FABP family members in liver cancer.

Article Snippet: The antibodies against FABP5 (39926), p53 (9282), BIRC5 (2808), CDK1 (77055), CDK2 (2546), CDK4 (12790), MCL-1 (94296) and GAPDH (2118) were purchased from Cell Signaling Technology (Danvers, MA, United States).

Techniques: Mutagenesis

Frequencies of genetic alternations and expression of FABP4 and FABP5 in various cancer types. A-B: Frequencies of genetic alternations of FABP4 in major cancer types using The Cancer Genome Atlas (TCGA) datasets via cBioportal (A) and in various liver cancer subtypes (B) using TCGA datasets via cBioportal; C-D: Frequencies of genetic alternations of FABP5 in pan-cancer types (C) and in various liver cancer subtypes (D) using TCGA datasets via cBioportal; E: FABP5 expression in liver cancer with different FABP5 genetic alteration types using TCGA datasets via cBioportal; F: Expression of FABP5 (left panel) and FABP4 (right panel) in liver cancer at stage I-IV using TCGA datasets via GEPIA2 portal. d P < 0.0001; NS: Not significant.

Journal: World Journal of Clinical Oncology

Article Title: Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma

doi: 10.5306/wjco.v15.i1.130

Figure Lengend Snippet: Frequencies of genetic alternations and expression of FABP4 and FABP5 in various cancer types. A-B: Frequencies of genetic alternations of FABP4 in major cancer types using The Cancer Genome Atlas (TCGA) datasets via cBioportal (A) and in various liver cancer subtypes (B) using TCGA datasets via cBioportal; C-D: Frequencies of genetic alternations of FABP5 in pan-cancer types (C) and in various liver cancer subtypes (D) using TCGA datasets via cBioportal; E: FABP5 expression in liver cancer with different FABP5 genetic alteration types using TCGA datasets via cBioportal; F: Expression of FABP5 (left panel) and FABP4 (right panel) in liver cancer at stage I-IV using TCGA datasets via GEPIA2 portal. d P < 0.0001; NS: Not significant.

Techniques: Expressing

Expression of FABP family members in tumor tissues and non-tumor tissue control in various cancer types. A-B: Expression of each FABP family member ( FABP1 , FABP2 , FABP3 , FABP4 , FABP5 , FABP6 , FABP7 , PMP2 , FABP9 and FABP12 ) in tumor tissues and non-tumor tissue control in various cancer types (A) and statistical significance when comparing their expression in tumor tissues with non-tumor tissue control (B) using GEPIA2 portal; C: Higher expression of FABP4 and FABP5, but not FABP1, was observed in liver tumor tissues comparing to non-tumor tissue control; D-E: High expression levels of FABP5, but not FABP1 or FABP4, in liver cancer correlate with overall patient survival (D) and disease-free survival (E). a P < 0.05.

Journal: World Journal of Clinical Oncology

Article Title: Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma

doi: 10.5306/wjco.v15.i1.130

Figure Lengend Snippet: Expression of FABP family members in tumor tissues and non-tumor tissue control in various cancer types. A-B: Expression of each FABP family member ( FABP1 , FABP2 , FABP3 , FABP4 , FABP5 , FABP6 , FABP7 , PMP2 , FABP9 and FABP12 ) in tumor tissues and non-tumor tissue control in various cancer types (A) and statistical significance when comparing their expression in tumor tissues with non-tumor tissue control (B) using GEPIA2 portal; C: Higher expression of FABP4 and FABP5, but not FABP1, was observed in liver tumor tissues comparing to non-tumor tissue control; D-E: High expression levels of FABP5, but not FABP1 or FABP4, in liver cancer correlate with overall patient survival (D) and disease-free survival (E). a P < 0.05.

Techniques: Expressing

Expression of FABP5 correlates with cancer hallmark G2M checkpoint and genes within. A: FABP5 positively correlated with enrichment of cancer hallmark G2M checkpoint in patients with liver hepatocellular carcinoma (LIHC); B: Gene list included in the cancer hallmark G2M checkpoint. The genes that showed positive correlation with FABP5 are highlighted in red ( P < 0.01); C: Highlighted genes in the G2M checkpoint gene set positively correlate with FABP5 expression in patients with LIHC. P values show the statistical significance of the correlation; R values indicate the correlation coefficient; D: Altered expression of individual genes in the G2M checkpoint gene set showed in the context of signaling network. Pink bars show upregulation of gene expression.

Journal: World Journal of Clinical Oncology

Article Title: Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma

doi: 10.5306/wjco.v15.i1.130

Figure Lengend Snippet: Expression of FABP5 correlates with cancer hallmark G2M checkpoint and genes within. A: FABP5 positively correlated with enrichment of cancer hallmark G2M checkpoint in patients with liver hepatocellular carcinoma (LIHC); B: Gene list included in the cancer hallmark G2M checkpoint. The genes that showed positive correlation with FABP5 are highlighted in red ( P < 0.01); C: Highlighted genes in the G2M checkpoint gene set positively correlate with FABP5 expression in patients with LIHC. P values show the statistical significance of the correlation; R values indicate the correlation coefficient; D: Altered expression of individual genes in the G2M checkpoint gene set showed in the context of signaling network. Pink bars show upregulation of gene expression.

Techniques: Expressing

Expression of FABP5 correlates with cancer hallmark TP53 signaling and genes within. A: FABP5 positively correlated with enrichment of cancer hallmark TP53 signaling in patients with liver hepatocellular carcinoma; B: Gene list included in TP53 signaling. The genes that showed positive correlation with FABP5 are highlighted in red; C: Highlighted genes in the TP53 signaling gene set positively correlate with FABP5 expression. P values show the statistical significance of the correlation; R values show the correlation coefficient; D: Altered expression of individual genes in the TP53 signaling gene set shown in the context of signaling network. Pink bars show upregulation of gene expression.

Journal: World Journal of Clinical Oncology

Article Title: Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma

doi: 10.5306/wjco.v15.i1.130

Figure Lengend Snippet: Expression of FABP5 correlates with cancer hallmark TP53 signaling and genes within. A: FABP5 positively correlated with enrichment of cancer hallmark TP53 signaling in patients with liver hepatocellular carcinoma; B: Gene list included in TP53 signaling. The genes that showed positive correlation with FABP5 are highlighted in red; C: Highlighted genes in the TP53 signaling gene set positively correlate with FABP5 expression. P values show the statistical significance of the correlation; R values show the correlation coefficient; D: Altered expression of individual genes in the TP53 signaling gene set shown in the context of signaling network. Pink bars show upregulation of gene expression.

Techniques: Expressing

Expression of FABP5 correlates with PLK1 and BIRC5 expression in pan cancer and liver cancer. A: Expression of FABP5 and other FABP family members as well as several highlighted genes CCNB1, TP53, BIRC5 and PLK1 in each cancer type using GEPIA2 portal ; B and C: FABP5 expression positively correlated with expression of BIRC5 at pan cancer (B) and liver cancer (C); D and E: FABP5 expression positively correlated with expression of PLK1 at pan cancer (D) and liver cancer (E); F and G: BIRC5 expression positively correlated with expression of PLK1 at pan cancer (F) and liver cancer (G). P values show the statistical significance of the correlation; R values show the correlation coefficient.

Journal: World Journal of Clinical Oncology

Article Title: Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma

doi: 10.5306/wjco.v15.i1.130

Figure Lengend Snippet: Expression of FABP5 correlates with PLK1 and BIRC5 expression in pan cancer and liver cancer. A: Expression of FABP5 and other FABP family members as well as several highlighted genes CCNB1, TP53, BIRC5 and PLK1 in each cancer type using GEPIA2 portal ; B and C: FABP5 expression positively correlated with expression of BIRC5 at pan cancer (B) and liver cancer (C); D and E: FABP5 expression positively correlated with expression of PLK1 at pan cancer (D) and liver cancer (E); F and G: BIRC5 expression positively correlated with expression of PLK1 at pan cancer (F) and liver cancer (G). P values show the statistical significance of the correlation; R values show the correlation coefficient.

Techniques: Expressing

Huh7 cells are sensitive to FABP5 inhibition by SFBI-26. A: Western blot shows the expression of FABP5, p53, and other proteins in Huh7 and HepG2 cells; B: 3-dose (0, 50 and 100 µmol/L) cell viability assay shows SBFI-26 inhibited the cell viability of hepatocellular carcinoma (HCC) cell lines Huh7 and HepG2 cells post treatment for 6 d; C: 8-dose (2-fold serial doses up to 100 µmol/L) cell viability assay showed SBFI-26 inhibited the cell viability of HCC cell lines post treatment for 6 d; D: 3-dose (0, 50 and 100 µmol/L) cell viability assay shows SBFI-26 inhibited the cell viability of Huh7 cells in time-dependent manner; E: 8-dose cell viability assay showed SBFI-26 inhibited the cell viability of Huh7 cells at 3- and 6-d post treatment; NS: Not significant.

Journal: World Journal of Clinical Oncology

Article Title: Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma

doi: 10.5306/wjco.v15.i1.130

Figure Lengend Snippet: Huh7 cells are sensitive to FABP5 inhibition by SFBI-26. A: Western blot shows the expression of FABP5, p53, and other proteins in Huh7 and HepG2 cells; B: 3-dose (0, 50 and 100 µmol/L) cell viability assay shows SBFI-26 inhibited the cell viability of hepatocellular carcinoma (HCC) cell lines Huh7 and HepG2 cells post treatment for 6 d; C: 8-dose (2-fold serial doses up to 100 µmol/L) cell viability assay showed SBFI-26 inhibited the cell viability of HCC cell lines post treatment for 6 d; D: 3-dose (0, 50 and 100 µmol/L) cell viability assay shows SBFI-26 inhibited the cell viability of Huh7 cells in time-dependent manner; E: 8-dose cell viability assay showed SBFI-26 inhibited the cell viability of Huh7 cells at 3- and 6-d post treatment; NS: Not significant.

Techniques: Inhibition, Western Blot, Expressing, Viability Assay

( A ) Expression analysis of FABP5 based on TCGA database. * p < 0.05; ** p < 0.01; *** p < 0.001. ( B ) Expression analysis of FABP5 based on TCGA and GTEx database. * p < 0.05. ( C ) Correlation between FABP5 expression and pathological stages of tumors.

Journal: Scientific Reports

Article Title: Oncogenic role and potential regulatory mechanism of fatty acid binding protein 5 based on a pan-cancer analysis

doi: 10.1038/s41598-023-30695-9

Figure Lengend Snippet: ( A ) Expression analysis of FABP5 based on TCGA database. * p < 0.05; ** p < 0.01; *** p < 0.001. ( B ) Expression analysis of FABP5 based on TCGA and GTEx database. * p < 0.05. ( C ) Correlation between FABP5 expression and pathological stages of tumors.

Article Snippet: Then, membranes got incubated with corresponding primary antibodies, including antibodies against FABP5 (1:1000, Biodragon, China) and β-actin (1:20,000, ABclonal, China), at 4 ℃ overnight.

Techniques: Expressing

Survival analysis of FABP5. ( A ) Overall survival analysis of FABP5. ( B ) Disease-free survival analysis of FABP5.

Journal: Scientific Reports

Article Title: Oncogenic role and potential regulatory mechanism of fatty acid binding protein 5 based on a pan-cancer analysis

doi: 10.1038/s41598-023-30695-9

Figure Lengend Snippet: Survival analysis of FABP5. ( A ) Overall survival analysis of FABP5. ( B ) Disease-free survival analysis of FABP5.

Techniques:

Journal: Scientific Reports

Article Title: Oncogenic role and potential regulatory mechanism of fatty acid binding protein 5 based on a pan-cancer analysis

doi: 10.1038/s41598-023-30695-9

Figure Lengend Snippet: Predicted upstream miRNAs of FABP5.

Techniques:

( A ) Correlation analysis between FABP5 and miR-577 in KIRC. ( B ) Expression analysis of miR-577 in KIRC. ( C ) Overall survival analysis of miR-577 in KIRC. ( D ) Correlation analysis of FABP5 with miR-22-3p in LIHC. ( E ) Expression analysis of miR-22-3p in LIHC. ( F ) Overall survival analysis of miR-22-3p in LIHC.

Journal: Scientific Reports

Article Title: Oncogenic role and potential regulatory mechanism of fatty acid binding protein 5 based on a pan-cancer analysis

doi: 10.1038/s41598-023-30695-9

Figure Lengend Snippet: ( A ) Correlation analysis between FABP5 and miR-577 in KIRC. ( B ) Expression analysis of miR-577 in KIRC. ( C ) Overall survival analysis of miR-577 in KIRC. ( D ) Correlation analysis of FABP5 with miR-22-3p in LIHC. ( E ) Expression analysis of miR-22-3p in LIHC. ( F ) Overall survival analysis of miR-22-3p in LIHC.

Techniques: Expressing

( A ) Binding sites of miR-22-3p on FABP5 predicted by PITA, miRmap and miRanda. ( B ) MicroRNA-22-3p expression measured in Hep3B and HepG2 cell lines via RT-qPCR. ( C ) The protein expression of FABP5 detected in Hep3B and HepG2 cell lines via Western Blot. ** p < 0.01; **** p < 0.0001.

Journal: Scientific Reports

Article Title: Oncogenic role and potential regulatory mechanism of fatty acid binding protein 5 based on a pan-cancer analysis

doi: 10.1038/s41598-023-30695-9

Figure Lengend Snippet: ( A ) Binding sites of miR-22-3p on FABP5 predicted by PITA, miRmap and miRanda. ( B ) MicroRNA-22-3p expression measured in Hep3B and HepG2 cell lines via RT-qPCR. ( C ) The protein expression of FABP5 detected in Hep3B and HepG2 cell lines via Western Blot. ** p < 0.01; **** p < 0.0001.

Techniques: Binding Assay, Expressing, Quantitative RT-PCR, Western Blot

( A ) Expression analysis of CD27-AS1, FGD5-AS1, GUSBP11, LINC00630, LINC00997, SNHG16 and TTC28-AS1 in LIHC. ( B ) Correlation analysis of FABP5 with CD27-AS1, GUSBP11, SNHG16 and TTC28-AS1 in LIHC. ( C ) Overall survival analysis of CD27-AS1, GUSBP11, SNHG16 and TTC28-AS1 in LIHC. ( D ) FABP5-related regulatory network in KIRC. ( E ) FABP5-related ceRNA regulatory network in LIHC.

Journal: Scientific Reports

Article Title: Oncogenic role and potential regulatory mechanism of fatty acid binding protein 5 based on a pan-cancer analysis

doi: 10.1038/s41598-023-30695-9

Figure Lengend Snippet: ( A ) Expression analysis of CD27-AS1, FGD5-AS1, GUSBP11, LINC00630, LINC00997, SNHG16 and TTC28-AS1 in LIHC. ( B ) Correlation analysis of FABP5 with CD27-AS1, GUSBP11, SNHG16 and TTC28-AS1 in LIHC. ( C ) Overall survival analysis of CD27-AS1, GUSBP11, SNHG16 and TTC28-AS1 in LIHC. ( D ) FABP5-related regulatory network in KIRC. ( E ) FABP5-related ceRNA regulatory network in LIHC.

Techniques: Expressing

( A ) Correlation between FABP5 and B cell infiltration. ( B ) Correlation between FABP5 and CD4+ T cell infiltration. ( C ) Correlation between FABP5 and CD8+ T cell infiltration. ( D ) Correlation between FABP5 and DC infiltration. ( E ) Correlation between FABP5 and macrophage infiltration. ( F ) Correlation between FABP5 and M1 macrophage infiltration. ( G ) Correlation between FABP5 and M2 macrophage infiltration. ( H ) Correlation between FABP5 and Treg infiltration. ( I ) Correlation between FABP5 and CAF infiltration.

Journal: Scientific Reports

Article Title: Oncogenic role and potential regulatory mechanism of fatty acid binding protein 5 based on a pan-cancer analysis

doi: 10.1038/s41598-023-30695-9

Figure Lengend Snippet: ( A ) Correlation between FABP5 and B cell infiltration. ( B ) Correlation between FABP5 and CD4+ T cell infiltration. ( C ) Correlation between FABP5 and CD8+ T cell infiltration. ( D ) Correlation between FABP5 and DC infiltration. ( E ) Correlation between FABP5 and macrophage infiltration. ( F ) Correlation between FABP5 and M1 macrophage infiltration. ( G ) Correlation between FABP5 and M2 macrophage infiltration. ( H ) Correlation between FABP5 and Treg infiltration. ( I ) Correlation between FABP5 and CAF infiltration.

Techniques:

( A ) Correlation between FABP5 and immune checkpoints in multiple tumor types. ( B ) Correlation between FABP5 and immune checkpoints in KIRC. ( C ) Correlation between FABP5 and immune checkpoints in LIHC.

Journal: Scientific Reports

Article Title: Oncogenic role and potential regulatory mechanism of fatty acid binding protein 5 based on a pan-cancer analysis

doi: 10.1038/s41598-023-30695-9

Figure Lengend Snippet: ( A ) Correlation between FABP5 and immune checkpoints in multiple tumor types. ( B ) Correlation between FABP5 and immune checkpoints in KIRC. ( C ) Correlation between FABP5 and immune checkpoints in LIHC.

Techniques:

Review

Structured Review

Images

Similar Products

Image Search Results